Challenge Model for Assessment of Human TB Immunity



Status:Completed
Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:18 - 45
Updated:1/31/2018
Start Date:June 9, 2014
End Date:December 18, 2017

Use our guide to learn which trials are right for you!

Phase I Open-Label Dose Escalation Trial for the Development of a Human BCG Challenge Model for Assessment of TB Immunity

This is a Phase I open-label, dose escalation trial to evaluate the use of Tice® BCG as a
challenge for future assessment of in vivo TB immunity. Subjects will be recruited from the
target population reflecting the community at 2 VTEU sites. Enrollment will occur over 14
months. Subjects who provide informed consent will be screened, and up to 120 eligible, HIV
and TB uninfected subjects, 18-45 years, inclusive, will be enrolled for study interventions
and sequentially assigned to 1 of 4 dose groups. Doses of Tice BCG from 2 to 16x10^6 cfu will
be delivered ID in a dose escalation format to 4 groups of 30 subjects per dose group.
Primary Objectives: 1) Evaluate the safety of different doses of ID Tice BCG for use as a
human challenge model for TB infection. 2) Examine shedding from ID challenge sites after
administration of different doses of Tice BCG in TB naive healthy subjects. 3) Evaluate the
reproducibility of BCG shedding over time with both quantitative PCR and culture.

This is a Phase I open-label, dose escalation trial to evaluate the use of Tice® BCG as a
challenge for future assessment of in vivo TB immunity. Subjects will be recruited from the
target population reflecting the community at large at 2 VTEU sites. It is anticipated that
enrollment will occur over a 14-month period. Subjects who provide informed consent will be
considered for eligibility (screened), and up to 120 eligible, willing, healthy, HIV and TB
uninfected subjects aged 18 to 45 years, inclusive, will be enrolled for study interventions
and sequentially assigned to 1 of 4 dose groups. Dose titrations of Tice® BCG from 2x10^6 cfu
to 16x10^6 cfu will be delivered intradermally in a dose escalation format to 4 groups of 30
subjects per dose group. In the first dose group, subjects will be immunized intradermally
with a single dose of 2x10^6 cfu Tice® BCG. The Tice® BCG doses will be increased
sequentially from 2x10^6 cfu to 4x10^6 cfu to 8x10^6 cfu to a maximum dose of 16x10^6 cfu
following assessment of safety and reactogenicity data from previous dose groups and sentinel
subjects. Following administration of Tice® BCG, intradermal (ID) site reactions will be
assessed for at least 30 minutes as well as by memory aid on a daily basis throughout the
first 15 days. Subjects will also return to the clinic on Days 22, 25, 29, 32, 36, 39, 43,
46, 50, 53, and 57 to evaluate the ID challenge site, assess for lymphadenopathy if indicated
based on review of interim medical history and clinical assessment, and review AEs/SAEs,
concomitant medications and health status, and collect and dispose of returned biohazard
materials. A final clinic visit will be performed at approximately 3 months (Day 99)
following administration of Tice® BCG to evaluate the ID challenge site, assess for
lymphadenopathy if indicated based on review of interim medical history and clinical
assessment, and review SAEs and health status. At approximately 6 months (Day 181) following
administration of Tice® BCG a telephone call will be performed to query for any SAEs that may
have occurred since the last visit. Based on this information, subjects may be asked to
return to the clinic to be evaluated. The duration of the study for each subject will be up
to approximately 7 to 8 months. Primary Objectives: 1) Evaluate the safety of different doses
of intradermal Tice® BCG for use as a human challenge model for Mycobacterium tuberculosis
infection. 2) Examine BCG shedding from intradermal challenge sites after administration of
different doses of Tice® BCG in TB naive healthy subjects. 3) Evaluate the reproducibility of
BCG shedding over time with both quantitative PCR and culture techniques. Secondary
objectives: 1) Determine a tolerable dose of intradermal Tice® BCG that will induce optimal
reproducibility of BCG shedding. 2) Determine the method of mycobacterial quantitation that
will result in the least variable results. 3) Characterize the magnitude and kinetics of BCG
shedding after intradermal Tice® BCG administration at 4 different doses. Parent protocol to
sub-study 12-0096.

Inclusion Criteria:

Eligibility Criteria for Study Entry:

- Provide written informed consent prior to initiation of any study procedures.

- Are males or non-pregnant females between the ages of 18 and 45 years, inclusive.

- Women of childbearing potential* in sexual relationships with men must use an
acceptable method of preventing conception** from 30 days prior to 3 months after
Tice® BCG administration.

*Not sterilized via tubal ligation, bilateral oophorectomy, hysterectomy, or
successful Essure placement (permanent, non-surgical, non-hormonal sterilization) with
documented radiological confirmation test at least 90 days after the procedure, and
still menstruating or < 1 year of the last menses if menopausal).

**Includes, but is not limited to, sexual abstinence, monogamous relationship with
vasectomized partner who has been vasectomized for 6 months or more prior to the
subject receiving Tice® BCG, barrier methods such as condoms or diaphragms with
spermicide or foam, effective intrauterine devices, NuvaRing®, successful Essure®
placement (permanent, non-surgical, non-hormonal sterilization) with documented
confirmation test at least 3 months after the procedure), and licensed hormonal
methods such as implants, injectables or oral contraceptives ("the pill").

- For women of childbearing potential, negative serum pregnancy test at screening and
negative urine pregnancy test within 24 hours prior to enrollment and Tice® BCG
administration.

- Are in good health, as judged by the investigator and determined by vital signs (oral
temperature, pulse, and blood pressure), medical history and physical examination.

- Have a negative HIV-1 ELISA test.

- Have negative serology tests for hepatitis B surface antigen and hepatitis C virus
antibody.

- Have a negative QuantiFERON®-TB Gold test. --Negative is defined as Nil response < 0.8
IU/ml and TB Antigen response minus Nil response < 0.35 IU/mL or TB Antigen response
minus Nil response > 0.35 IU/mL and < 25% of Nil response and Mitogen response minus
Nil response > 0.5 IU/ml.

- Have a urine dipstick for protein less than 1.

- Have a urine dipstick negative for glucose.

- Ability to understand and complete all study visits as required per protocol and be
reachable by telephone.

Exclusion Criteria:

Exclusion Criteria for Study Entry:

-Have a history of suspected, confirmed, treated or have other evidence of active
tuberculosis. Symptoms may include recurrent fever, fatigue, night sweats, weight loss,
oral ulcers, diarrhea, nausea, vomiting, or bleeding.

-Have any systemic symptoms* within 72 hours before Tice® BCG administration or signs of
lymphadenopathy, hepatosplenomegaly, or pulmonary disease by physical examination on day of
Tice® BCG administration.

- Includes fever, chills, malaise, fatigue, headache, night sweats, weight loss, nausea,
vomiting, bleeding, diarrhea, abdominal pain, rhinorrhea, cough, wheezing, or
shortness of breath.

-Have history of any significant acute or chronic medical conditions* or need for
chronic medications that, in the opinion of the investigator, will interfere with
immunity or affect safety.

- Includes, but is not limited to, disorders of the liver, kidney, lung, heart, or
nervous system, or other metabolic or autoimmune/inflammatory conditions.

-Have any history of excessive scarring or keloid formation.

-Have household contact or occupation involving significant contact with someone who
is immunocompromised*.

- Includes persons with HIV, AIDs, or active cancer; infants (children < 1 year);
pregnant women; or persons who are immunosuppressed for approximately 6 weeks (during
the time of active ID lesion drainage).

-Have a history of epilepsy. (Does not include febrile seizures as a child).

- Have a pacemaker, prosthetic valve, or implantable cardiac devices.

- Have a history of bleeding disorder.

- Have a known allergy to any Tice® BCG components (glycerin, asparagine, citric
acid, potassium phosphate, magnesium sulfate, iron ammonium citrate, and
lactose).

- Received blood products or immunoglobulin within 6 months prior to Tice® BCG
administration.

- Received immunotherapy within one year prior to Tice® BCG administration.

- Received or plan to receive live attenuated vaccines 4 weeks before or after
Tice® BCG administration.

- Received or plan to receive inactivated or killed vaccines 2 weeks before or
after Tice® BCG administration.

- Plans to enroll in another clinical trial* that could interfere with safety
assessment of the investigational product at any time during the study period.

- Includes trials that have a study intervention such as a drug, biologic, or device.

-Received an experimental agent* within 30 days prior to Tice® BCG administration or
planned receipt of an experimental agent within 90 days after Tice® BCG
administration.

- Includes vaccine, drug, biologic, device, blood product, or medication.

- Have a history of use of a systemic antibiotic within 14 days prior to Tice® BCG
administration or planned use of a systemic antibiotic for 3 months after Tice®
BCG administration.

- Have any medical, psychiatric, occupational, or behavioral problems that make it
unlikely for the subject to comply with the protocol as determined by the
investigator.

- Are health care providers at the highest risk of acquiring Mtb infection, such as
pulmonologists performing bronchoscopies on TB patients.

- Are breastfeeding or plan to breastfeed at any given time throughout the study.

- Have long term use* of high dose oral or parenteral glucocorticoids**, or
high-dose inhaled steroids***.

- Defined as taken for 2 weeks or more in total at any time during the past 2 months.

- High dose defined as prednisone >/= 20 mg total daily dose, or equivalent dose of
other glucocorticoids.

- High dose defined as > 800 mcg/day of beclomethasone dipropionate or
equivalent.

If short term corticosteroids are given, then the subject should not receive Tice® BCG or
have blood collected for immunogenicity studies within 1 week of steroid administration.

- Have immunosuppression or are taking systemic immunosuppressants as a result of an
underlying illness or treatment.

- Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 36 months prior
to Tice® BCG administration.

- Any active neoplastic disease.

- Have a pulse rate less than 50 bpm or greater than 100 bpm.

- Have a systolic blood pressure less than 90 mm Hg or greater than 140 mm Hg.

- Have a diastolic blood pressure less than 50 mm Hg or greater than 90 mmHg.

- Have a WBC less than 4.0x10^3/UL or greater than 10.5x10^3/UL.

- Have hemoglobin less than 11.5x10^3/UL (female) or less than 12.5x10^3/UL (male).

- Have a platelet count less than 140x10^3/UL.

- Have a creatinine greater than 1.30 mg/dL.

- Have an ALT (SGPT) greater than 40 IU/L (female) or greater than 55 IU/L (male).

- Have known HIV, Hepatitis B, or Hepatitis C infection.

- Have a history of alcohol or drug abuse in the last 5 years.

- Have had a positive PPD skin test in the past or received BCG vaccine (BCG vaccination
history will be determined by self-report, country of birth, and/or evidence of BCG
scar).

- Have a BMI >35.

- PPD skin test within 2 months prior to Tice® BCG administration or planned receipt
during the study other than from participation in this study.

- Oral temperature >/= 100.4°F (>/= 38.0°C) or other symptoms of an acute illness within
3 days before Tice® BCG administration. (Subject may be rescheduled).

- Any medical disease or condition that, in the opinion of the investigator, is a
contraindication to study participation*.

- Includes medical disease or condition that would place the subject at an
unacceptable risk of injury, render them unable to meet the requirements of the
protocol, or may interfere with the evaluation of responses or their successful
completion of the study.
We found this trial at
2
sites
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Decatur, GA
Click here to add this to my saved trials